Company: DHR
Filing Date: 2025-02-20
Form Type: 10-K
Source: 0000313616-25-000043
Chunk: 43

Company: DANAHER CORP /DE/
Filing Date: 2025-02-20
Form: 10-K
Item: Item 8
Chunk 43
---
 the Life Sciences segment.  This determination was primarily the result of softness in the genomics market, including but not limited to the discontinuation of drug development programs announced in the third quarter and weaker demand at some of the business’s larger customers as well as reduced demand due to the reprioritization of drug development programs at other customers.  The Company engaged a third-party valuation specialist to assist in the valuation of the trade name using a relief from royalty method of valuation.  The significant assumptions in the relief from royalty method include, but were not limited to, revenue growth rates (including perpetual growth rates), royalty rates and discount rates.  The Company recorded a noncash impairment 

79

charge of $222 million pretax ($169 million after-tax) related to the indefinite-lived trade name for the year ended December 31, 2024.  After recognition of the impairment, the net book value of the trade name was $508 million and the Company continues to monitor for any changes to the business performance or key assumptions.  In connection with the trade name impairment, the Company also tested the related asset group and the related reporting unit goodwill for impairment in the third quarter of 2024, and in both cases the Company identified no impairment.  In the fourth quarter of 2024, the Company identified impairment triggers for a trade name in the Diagnostics segment and recorded an impairment charge of $43 million.      Additionally, the Company identified impairment triggers in the second quarter of 2023 in the Biotechnology segment and the fourth quarter of 2023 in the Diagnostics and Biotechnology segments which resulted in the impairment of certain long-lived assets, including technology and other assets.  In 2023, the Company recorded impairment charges totaling $77 million.  The 2024 and 2023 impairment charges were recorded in selling, general and administrative expenses in the accompanying Consolidated Statements of Earnings.  During 2022 there were no impairments of intangible assets.Total intangible amortization expense in 2024, 2023 and 2022 was approximately $1.6 billion, $1.5 billion and $1.4 billion, respectively.  Based on the intangible assets recorded as of December 31, 2024, amortization expense is estimated to be approximately $1.6 billion during 2025, $1.6 billion during 2026, $1.5 billion during 2027, $1.5 billion during 2028 and $1